Ari Harjula

Ari Harjula

Auto-generated profile, based on publicly available information

Ari Harjula

Department of Cardiothoracic Surgery, Helsinki University Meilahti Hospital, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2012 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
KNKristo Nuutila
Kristo Nuutila
ASAntti Siltanen
Antti Siltanen
MPMatti Peura
Matti Peura
JBJozef Bizik
Jozef Bizik
IKIlkka Kaartinen
Ilkka Kaartinen
EKEsko Kankuri
Esko Kankuri

1 June 2014 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
TPTommi Pätilä
Tommi Pätilä
MLMiia Lehtinen
Miia Lehtinen
AVAntti Vento
Antti Vento
JSJukka Schildt
Jukka Schildt
JSJuha Sinisalo
Juha Sinisalo
AHAri Harjula
Ari Harjula

1 January 2007 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JLJuho T. Lehto
Juho T. Lehto
MHMaija Halme
Maija Halme
PTPentti Tukiainen
Pentti Tukiainen
AHAri Harjula
Ari Harjula
JSJorma Sipponen
Jorma Sipponen
ILIrmeli Lautenschlager
Irmeli Lautenschlager

1 June 2013 in Burns
Verified
Journal Article
Closed access
KNKristo Nuutila
Kristo Nuutila
ASAntti Siltanen
Antti Siltanen
MPMatti Peura
Matti Peura
AHAri Harjula
Ari Harjula
TNTapio Nieminen
Tapio Nieminen
PAPertti Aarnio
Pertti Aarnio

26 April 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAntti Siltanen
Antti Siltanen
KKKatsukiyo Kitabayashi
Katsukiyo Kitabayashi
PLPäivi Lakkisto
Päivi Lakkisto
JMJohanna Mäkelä
Johanna Mäkelä
TPTommi Pätilä
Tommi Pätilä
AHAri Harjula
Ari Harjula
After severe myocardial infarction (MI), heart failure results from ischemia, fibrosis, and remodeling. A promising therapy to enhance cardiac function and induce therapeutic angiogenesis via a paracrine mechanism in MI is myoblast sheet transplantation. We hypothesized that in a rat model of MI-induced chronic heart failure, this therapy could be further improved by overexpression of the antiapoptotic, antifibrotic, and proangiogenic hepatocyte growth factor (HGF) in the myoblast sheets. We studied the ability of wild type (L6-WT) and human HGF-expressing (L6-HGF) L6 myoblast sheet-derived paracrine factors to stimulate cardiomyocyte, endothelial cell, or smooth muscle cell migration in culture. Further, we studied the autocrine effect of hHGF-expression on myoblast gene expression profiles by use of microarray analysis. We induced MI in Wistar rats by left anterior descending coronary artery (LAD) ligation and allowed heart failure to develop for 4 weeks. Thereafter, we administered L6-WT (n = 15) or L6-HGF (n = 16) myoblast sheet therapy. Control rats (n = 13) underwent LAD ligation and rethoracotomy without therapy, and five rats underwent a sham operation in both surgeries. We evaluated cardiac function with echocardiography at 2 and 4 weeks after therapy, and analyzed cardiac angiogenesis and left ventricular architecture from histological sections at 4 weeks. Paracrine mediators from L6-HGF myoblast sheets effectively induced migration of cardiac endothelial and smooth muscle cells but not cardiomyocytes. Microarray data revealed that hHGF-expression modulated myoblast gene expression. In vivo, L6-HGF sheet therapy effectively stimulated angiogenesis in the infarcted and non-infarcted areas. Both L6-WT and L6-HGF therapies enhanced cardiac function and inhibited remodeling in a similar fashion. In conclusion, L6-HGF therapy effectively induced angiogenesis in the chronically failing heart. Cardiac function, however, was not further enhanced by hHGF expression.

6 July 2009 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
MPMatti Peura
Matti Peura
JBJozef Bizik
Jozef Bizik
PSPertteli Salmenperä
Pertteli Salmenperä
ANAriel Noro
Ariel Noro
MKMatti Korhonen
Matti Korhonen
EKEsko Kankuri
Esko Kankuri